far
monoclon
antibodi
develop
treat
cancer
immunolog
diseas
howev
global
spread
infect
west
nile
corona
virus
need
address
potenti
threat
bioterror
boost
public
interest
govern
support
countermeasur
infecti
diseas
attract
featur
monoclon
antibodi
high
specif
effect
recruit
immun
system
would
seem
make
excel
candid
antiinfect
agent
analys
trend
develop
approv
antiinfect
monoclon
antibodi
discuss
factor
influenc
success
past
decad
monoclon
antibodi
mab
becom
thrive
class
therapeut
receiv
regulatori
approv
clinic
develop
major
agent
develop
treat
cancer
immun
disord
owe
least
part
welldefin
unmet
medic
need
market
area
howev
mab
also
investig
potenti
antiinfect
agent
although
limit
success
far
mab
approv
us
fda
one
antiinfect
agent
nevertheless
numer
candid
undergo
preclin
clinic
studi
ampl
medic
need
exist
target
antiinfect
treatment
care
select
indic
mab
characterist
specif
avid
isotyp
opportun
exist
develop
safe
efficaci
antiinfect
mab
would
complement
arsen
vaccin
antiinfect
drug
caution
advis
despit
increas
govern
fund
develop
market
countermeasur
mani
pathogen
yet
clearli
defin
part
ongo
effort
track
trend
develop
approv
therapeut
mab
tuft
center
studi
drug
develop
collect
data
commerci
sponsor
antiinfect
mab
preclin
clinic
stage
develop
see
box
inclus
criteria
probabl
success
calcul
product
enter
clinic
studi
vaccin
antiinfect
drug
potenti
market
competitor
compar
antiinfect
mab
clinic
develop
market
pipelin
vaccin
antiinfect
drug
assess
overlap
target
organ
technolog
product
mab
develop
late
although
therapeut
mab
enter
clinic
studi
antiinfect
product
concept
mab
magic
bullet
capabl
home
specif
target
caught
imagin
scientist
businesspeopl
public
practic
idea
commonli
appli
cancer
therapeut
war
cancer
declar
efficaci
oncolog
product
still
much
demand
decad
later
nevertheless
number
compani
explor
judici
use
antiinfect
mab
area
medic
need
yet
unmet
vaccin
antiinfect
drug
exampl
cytomegaloviru
hepat
b
viru
human
immunodefici
viru
hiv
human
rhinoviru
infect
sepsi
origin
mab
product
method
fusion
mous
lymphocyt
myeloma
cell
provid
murin
mab
product
often
immunogen
human
mab
prefer
therapeut
eleven
antiinfect
mab
clinic
studi
seven
human
four
murin
product
time
human
mab
deriv
human
blymphocyt
natur
infect
patient
sourc
cell
limit
number
pathogen
could
target
earli
hybridoma
method
lent
prepar
immunoglobulin
igm
mab
well
versatil
igg
product
eleven
mab
four
igm
antibodi
howev
igm
antibodi
compos
five
monom
four
protein
chain
compris
monom
limit
util
therapeut
larg
size
igm
antibodi
larg
confin
circulatori
system
product
studi
primarili
treatment
bloodstream
bacteri
infect
sepsi
contrast
major
igg
mab
studi
treatment
viral
infect
overal
approv
success
rate
antiinfect
mab
studi
zero
eleven
product
enter
clinic
studi
five
product
progress
phase
ii
three
progress
phase
iii
two
advanc
fda
review
neither
applic
approv
two
product
review
fda
edobacomab
xoma
nebacumab
centoxin
centocor
igm
antibodi
studi
treatment
gramneg
septicaemia
addit
efficaci
test
request
fda
review
edobacomab
product
meet
endpoint
improv
shortterm
surviv
addit
studi
develop
nebacumab
termin
due
excess
mortal
sepsi
patient
treat
later
diagnos
without
gramneg
bacteraemia
nebacumab
approv
number
countri
outsid
us
voluntarili
withdrawn
market
technolog
advanc
open
new
opportun
genet
engin
mab
chimer
human
bispecif
product
began
enter
clinic
larg
number
phagedisplay
transgen
mous
technolog
made
human
mab
readili
avail
develop
therapeut
mab
enter
clinic
studi
doubl
number
studi
howev
perhap
highprofil
product
termin
previou
decad
mab
studi
antiinfect
agent
antiinfect
mab
develop
focus
antivir
therapeut
compris
total
studi
antihiv
mab
intensifi
one
antihiv
mab
studi
wherea
six
product
clinic
varieti
specif
larg
though
four
mab
target
region
hiv
glycoprotein
overal
approv
success
rate
calcul
antiinfect
mab
studi
three
mab
remain
phase
ii
clinic
studi
rate
increas
slightli
two
murin
product
remov
analysi
clinic
phasetransit
probabl
probabl
move
one
clinic
phase
next
transit
phase
ii
phase
ii
iii
phase
iii
us
approv
respect
fig
one
antiinfect
mab
studi
palivizumab
synagi
medimmun
review
fda
approv
june
treatment
respiratori
syncyti
viru
infect
highrisk
paediatr
patient
previous
publish
phasetransit
probabl
human
mab
stratifi
time
therapeut
categori
human
mab
compris
usapprov
mab
abund
three
main
varieti
mab
chimer
human
human
clinic
studi
phasetransit
probabl
antiinfect
mab
develop
fell
short
benchmark
set
human
mab
clinic
studi
similar
period
well
oncolog
immunolog
diseas
fig
problemat
step
antiinfect
mab
success
complet
phase
iii
three
nonmurin
antiinfect
mab
enter
phase
iii
one
palivizumab
success
wherea
two
termin
phase
iii
due
lack
efficaci
industri
focu
mab
product
intensifi
therapeut
mab
enter
clinic
studi
januari
june
pace
continu
total
decad
could
approach
product
howev
case
two
previou
decad
antiinfect
mab
still
compris
small
percentag
total
product
develop
date
first
year
mab
treatment
infecti
diseas
enter
clinic
studi
earli
stage
develop
phase
nine
phase
ii
two
enter
phase
iii
studi
tabl
averag
length
clinic
develop
phase
fdaapprov
mab
year
surpris
product
still
undergo
evalu
success
rate
calcul
antiinfect
mab
compris
current
cohort
agent
still
clinic
studi
predict
base
success
rate
cohort
suggest
two
three
product
might
approv
howev
due
small
size
cohort
result
must
consid
estim
addit
number
factor
might
improv
success
rate
cohort
includ
human
mab
number
mab
fasttrack
design
genet
engin
human
mab
compris
major
antiinfect
product
might
higher
probabl
success
compar
chimer
human
product
accur
assess
success
rate
yet
possibl
human
mab
therapeut
categori
complet
develop
process
one
fdaapprov
far
adalimumab
humira
abbott
receiv
approv
decemb
treatment
rheumatoid
arthriti
four
mab
current
cohort
fda
fasttrack
design
treatment
bacteri
bacillu
anthraci
staphylococcu
viral
infect
sinc
found
tuft
center
studi
drug
develop
collect
data
clinic
develop
approv
therapeut
vaccin
data
monoclon
antibodi
mab
collect
survey
pharmaceut
biotechnolog
firm
compani
web
site
public
document
exampl
press
releas
annual
report
commerci
avail
databas
im
r
focu
pharmaproject
access
verifi
statu
product
product
phase
iii
assign
phase
ii
product
phase
iiiii
assign
phase
iii
data
updat
chang
note
june
mab
data
set
compris
total
therapeut
product
enter
clinic
studi
sponsor
commerci
firm
product
either
origin
sponsor
compani
licens
commerci
govern
academ
sourc
mab
identifi
antiinfect
agent
clinic
statu
product
follow
phase
phase
ii
two
phase
iii
one
approv
us
countri
discontinu
statu
antiinfect
mab
preclin
develop
sponsor
commerci
firm
assess
june
approv
success
calcul
base
product
known
fate
us
approv
discontinu
percent
complet
defin
percent
product
known
fate
given
cohort
phasetransit
probabl
calcul
follow
number
product
complet
given
phase
enter
next
divid
differ
number
product
enter
phase
still
phase
time
calcul
transit
occur
phase
clinic
studi
conduct
worldwid
includ
hepat
c
hiv
avail
sinc
fasttrack
design
intend
facilit
develop
medicin
product
might
improv
exist
therapi
avail
patient
seriou
lifethreaten
diseas
compani
sponsor
fasttrack
product
elig
frequent
time
interact
fda
fasttrack
product
applic
elig
roll
review
section
file
time
although
benefit
obvious
affect
overal
safeti
efficaci
product
might
improv
qualiti
clinic
develop
programm
market
applic
increas
speed
fda
review
decreas
likelihood
termin
commerci
reason
examin
compani
preclin
pipelin
assess
number
antiinfect
mab
might
enter
clinic
remaind
decad
product
compani
programm
assign
three
categori
preclin
categori
compris
discret
clearli
defin
mab
test
anim
earli
research
categori
compris
singl
mab
group
sever
mab
vitro
data
exampl
target
organ
neutral
data
screen
categori
compris
mab
librari
gener
screen
programm
preclin
mab
product
programm
sponsor
sole
govern
academ
institut
exclud
discoveri
institut
might
licens
commerci
futur
result
like
undercount
total
possibl
mab
candid
unknown
amount
found
preclin
group
compris
eleven
product
investig
eight
compani
interestingli
select
target
seem
strongli
influenc
categori
b
c
prioriti
pathogen
list
use
us
center
diseas
control
prevent
nation
institut
health
nih
categori
agent
highest
prioriti
includ
pathogen
easili
dissemin
transmit
persontoperson
preclin
product
eight
target
categori
b
c
pathogen
tabl
nearli
half
product
potenti
treatment
either
anthrax
categori
three
mab
west
nile
viru
categori
b
two
mab
infect
contrast
six
mab
current
clinic
studi
none
discontinu
mab
direct
toward
pathogen
prioriti
pathogen
list
earli
research
screen
group
contain
specul
product
programm
total
potenti
product
compani
identifi
earli
research
though
present
preclin
group
mab
therapeut
hiv
hepat
b
c
infect
reappear
earli
research
group
four
mab
prioriti
pathogen
includ
one
anthrax
rabi
sever
acut
respiratori
syndrom
sar
variola
infect
screen
group
compris
antiinfect
mab
programm
compani
screen
programm
mab
target
hiv
hepat
b
c
well
four
prioriti
pathogen
clostridium
botulinum
ebola
viru
sarsassoci
corona
viru
variola
viru
identifi
target
five
programm
disclos
remain
seen
whether
programm
gener
clinic
candid
compani
develop
antiinfect
mab
jockey
posit
market
two
group
product
vaccin
antiinfect
drug
presenc
competit
product
could
one
explan
dearth
antiinfect
mab
develop
examin
market
pipelin
vaccin
antiinfect
drug
assess
whether
product
might
provid
competit
mab
develop
focus
product
target
hepat
c
hiv
viral
infect
b
anthraci
pathogen
escherichia
coli
staphylococcu
bacteri
infect
antiinfect
mab
clinic
tabl
treatment
five
pathogen
although
theori
prevent
infect
would
desir
compar
treatment
vaccin
current
market
us
one
relev
pathogen
anthrax
anthrax
vaccin
conveni
six
dose
must
administ
interv
recommend
person
thought
risk
exposur
vaccin
develop
five
target
organ
though
earli
stage
clinic
studi
eight
vaccin
phase
four
vaccin
phase
ii
studi
hepat
c
b
anthraci
pathogen
e
coli
staphylococcu
infect
least
hiv
vaccin
current
earli
clinic
studi
sponsor
least
part
compani
nonprofit
institut
govern
agenc
worldwid
involv
develop
mani
hiv
vaccin
extent
commerci
involv
develop
unclear
well
known
none
hiv
vaccin
yet
shown
great
deal
promis
antiinfect
drug
market
treatment
five
pathogen
howev
mani
drug
viral
pathogen
except
effect
inhibit
cure
infect
caus
seriou
side
effect
antibacteri
drug
ciprofloxacin
bayer
efficaci
mild
case
cutan
anthrax
though
effect
inhal
pathogen
infect
pathogen
e
coli
manag
support
care
though
develop
haemolyt
urem
syndrom
infect
paediatr
patient
remain
seriou
problem
number
drug
effect
staphylococcu
strain
resist
mani
drug
number
antiinfect
drug
earli
stage
clinic
studi
treatment
hepat
c
hiv
two
current
phase
ii
studi
viramidin
valeant
pharmaceut
hepat
c
maraviroc
pfizer
hiv
product
studi
treatment
three
bacteri
pathogen
none
latestag
develop
pathogen
e
coli
infect
pose
especi
difficult
challeng
antiinfect
drug
develop
nonpathogen
strain
benefici
intestin
flora
antiinfect
drug
usual
select
enough
differenti
one
varieti
technolog
advanc
compani
increasingli
exploit
benefit
mab
exampl
high
specif
effect
recruit
immun
system
reduc
obstacl
develop
exampl
antimab
immun
reaction
complex
product
gener
uniqu
function
higher
probabl
approv
success
mab
compar
small
molecul
make
attract
diversif
compani
pipelin
howev
small
number
antiinfect
mab
current
clinic
studi
seem
readi
enter
clinic
challeng
specif
develop
mab
antiinfect
agent
clearli
caus
compani
proceed
caution
area
treatment
mab
passiv
immun
unlik
vaccin
antiinfect
mab
provid
shortterm
prophylaxi
parenter
rout
administr
mab
decidedli
less
conveni
oral
administr
mani
antiinfect
drug
product
mab
complic
costli
compar
mani
vaccin
drug
far
optimist
overal
approv
success
rate
calcul
antiinfect
mab
lower
antiinfect
drug
produc
major
pharmaceut
firm
though
must
note
approv
antiinfect
drug
deriv
version
previous
success
product
wherea
approv
antiinfect
mab
novel
consequ
factor
competit
vaccin
antiinfect
drug
focus
mab
develop
nich
applic
medic
need
exist
new
treatment
opportun
success
antiinfect
mab
develop
exist
nich
applic
howev
return
necessarili
small
exampl
fdaapprov
mab
treatment
respiratori
syncyti
viru
highrisk
infant
palivizumab
global
sale
nearli
billion
dollar
addit
landscap
antiinfect
develop
us
chang
due
recent
legisl
increas
emphasi
nation
institut
health
prioriti
pathogen
chang
fda
regul
specif
numer
opportun
current
avail
develop
antiinfect
mab
bioterror
countermeasur
need
safe
effect
antiinfect
agent
taken
ad
urgenc
sinc
septemb
recent
us
legisl
made
substanti
amount
money
avail
approv
juli
project
bioshield
act
amend
public
health
servic
act
specif
provid
protect
countermeasur
chemic
radiolog
nuclear
agent
may
use
terrorist
attack
unit
state
give
nation
institut
health
nih
contract
flexibl
infrastructur
improv
expedit
scientif
peer
review
process
streamlin
food
drug
administr
approv
process
countermeasur
author
appropri
us
billion
fiscal
year
given
achiev
desir
goal
project
bioshield
provid
financi
incent
exampl
govern
purchas
contract
compani
invest
develop
bioterror
countermeasur
howev
must
note
far
compani
entic
opportun
due
part
lack
clearli
defin
market
result
product
valid
product
preclin
earli
clinic
studi
though
phase
cover
everi
request
applic
issu
nih
develop
antiinfect
agent
also
facilit
use
fda
regul
colloqui
refer
anim
rule
rule
propos
publish
final
form
anim
rule
state
fda
approv
may
base
evid
effect
adequ
wellcontrol
studi
anim
howev
safeti
human
must
also
establish
result
anim
studi
must
establish
product
reason
like
produc
clinic
benefit
human
approv
rule
therefor
absolut
requir
exist
appropri
anim
model
infecti
diseas
anim
rule
regul
specifi
evid
need
demonstr
effect
new
drug
biolog
drug
product
human
efficaci
studi
ethic
feasibl
condit
exist
number
antiinfect
bioterror
countermeasur
usual
uneth
induc
encourag
infect
human
subject
mean
studi
product
effect
rigor
efficaci
studi
feasibl
case
uncommon
natur
infect
anthrax
infect
number
string
come
attach
approv
rule
postmarket
studi
must
done
studi
ethic
feasibl
fda
may
restrict
distribut
ensur
safe
use
patient
label
must
explain
approv
base
efficaci
studi
conduct
anim
alon
antiinfect
mab
develop
difficult
endeavour
prevail
condit
open
new
opportun
tradit
approach
use
vaccin
antiinfect
drug
fail
control
spread
number
infecti
agent
need
novel
therapeut
still
exist
greater
appreci
eas
intent
unintent
spread
infecti
agent
caus
govern
make
addit
fund
avail
develop
antiinfect
product
modifi
regul
approv
compani
need
capit
opportun
meet
need
new
antiinfect
mab
though
caution
advis
case
market
product
well
defin
